These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32914068)

  • 1. Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus.
    Kurokawa M; Naito S; Ito S; Takai S; Kawamura Y; Kaneko H; Kakizaki H; Tsuchiya N
    IJU Case Rep; 2020 Sep; 3(5):181-183. PubMed ID: 32914068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial Comment to Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus.
    Hatakeyama S; Ohyama C
    IJU Case Rep; 2020 Sep; 3(5):183-184. PubMed ID: 32914069
    [No Abstract]   [Full Text] [Related]  

  • 3. Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma.
    Hayakawa N; Kikuchi E; Suzuki S; Oya M
    Int Cancer Conf J; 2020 Jul; 9(3):123-126. PubMed ID: 32582515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset.
    Aoki S; Yasui M; Tajirika H; Terao H; Funahashi M; Ohta J
    Case Rep Oncol; 2020; 13(3):1490-1494. PubMed ID: 33564288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy.
    Kawahara T; Mochizuki T; Sugimura R; Izumi K; Kuroda S; Miyoshi Y; Nakaigawa N; Yao M; Tanabe M; Uemura H
    Case Rep Oncol; 2019; 12(2):548-553. PubMed ID: 31427950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome.
    Oki R; Urasaki T; Ueki A; Inamura K; Komai Y; Takahashi S; Yonese J; Yuasa T
    IJU Case Rep; 2023 Jan; 6(1):33-36. PubMed ID: 36605683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency.
    Pang X; Qian J; Jin H; Zhang L; Lin L; Wang Y; Lei Y; Zhou Z; Li M; Zhang H
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma.
    Nishimura N; Miyake M; Shimizu T; Tachibana A; Tanaka N; Fujimoto K
    IJU Case Rep; 2022 Sep; 5(5):338-341. PubMed ID: 36090940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma.
    Xu Z; Ma J; Chen T; Yang Y
    Front Immunol; 2022; 13():978266. PubMed ID: 36458005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney.
    Kamei J; Yokoyama H; Niki T; Suda R; Sugihara T; Fujisaki A; Ando S; Iwami D; Fujimura T
    IJU Case Rep; 2022 May; 5(3):199-202. PubMed ID: 35509786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary hypertension on systemic sclerosis-lupus erythematosus overlap syndrome.
    Rachdi I; Tougorti M; Daoud F; Aydi Z; Zoubeidi H; Ben Dhaou B; Boussema F
    Ann Cardiol Angeiol (Paris); 2019 Oct; 68(4):221-225. PubMed ID: 30685083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma.
    Fukiishi Y; Fukuhara H; Kurano Y; Shugimoto H; Yamashita E; Karasima T; Inoue K
    IJU Case Rep; 2023 Mar; 6(2):128-132. PubMed ID: 36874988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
    Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
    Nishiyama N; Kita Y; Ito K; Kato M; Hatakeyama S; Matsushita Y; Naito S; Miyake M; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Nishiyama H; Kobayashi T; Kitamura H;
    Anticancer Res; 2023 Nov; 43(11):5041-5050. PubMed ID: 37909969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
    Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
    Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis.
    Ishii A; Yokoyama M; Tsuji H; Fujii Y; Tamaoka A
    eNeurologicalSci; 2020 Jun; 19():100236. PubMed ID: 32211521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatitis as immune-related adverse event during pembrolizumab therapy for multiple lung metastases from renal pelvic cancer.
    Kokura K; Watanabe J; Takuma T; Yokozeki H; Uketa S; Uemura Y
    IJU Case Rep; 2023 Nov; 6(6):402-405. PubMed ID: 37928307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report.
    Isoda B; Shiga M; Kandori S; Nagumo Y; Yoshino T; Ikeda A; Kawahara T; Kimura T; Negoro H; Hoshi A; Mathis BJ; Nishiyama H
    Case Rep Oncol; 2023; 16(1):414-418. PubMed ID: 37384209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A young girl with chronic isolated cervical lymphadenopathy found to have lupus lymphadenopathy, progressing to develop lupus nephritis: a case report.
    Jayawickreme KP; Subasinghe S; Weerasinghe S; Perera L; Dissanayaka P
    J Med Case Rep; 2021 Jun; 15(1):328. PubMed ID: 34176492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.